SCHEMBL28943227

SCHEMBL28943227

O=C(O)c1cc(NC2CC2)nc(N2CCOCC2)n1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 10/20 0.53
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KMO O15229 1/20 0.43
▸ PIK3R1 P27986 1/20 0.42
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000081 0.96 PIK3CA (0.56) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL27172434 0.96 PIK3CA (0.56) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL23304407 0.91 ALDH1A1 (0.46) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL23684180 0.86 PIK3CA (0.46) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL23304305 0.83 CHRM3 (0.45) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL27172385 0.83 PIK3CA (0.53) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL30060484 0.83 PIK3CA (0.53) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL27681005 0.83 ALDH1A1 (0.63) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL5247155 0.83 ALDH1A1 (0.54) PIK3CAALDH1A1KDM4EMEN1KMT2A
SCHEMBL23304360 0.81 GAA (0.40) PIK3CAALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101023063-A Azine-carboxamides as anti-cancer agents ASTRAZENECA AB (SE) 2007-08-22 — — CN disclosed
Send feedback